Cardiol Therapeutics says net proceeds will fund development and expenses
Net proceeds will support CardiolRx, CRD-38 development and general expenses.
Related stories
Caterpillar Publishes Q3 2026 Earnings Call Transcript
M impact | EQUITY | Nov 03, 2026, 11:58 PM UTC
American Financial Group Reports Quarterly Results
American Financial Group reported results for the quarter ended September 30; the available report provides no figures.
M impact | EQUITY | Nov 03, 2026, 11:57 PM UTC
Matador Resources Reports Quarterly Results Through September 30
Matador Resources reported results for the quarter ended September 30.
M impact | EQUITY | Nov 03, 2026, 11:54 PM UTC
EIKEN Chemical Publishes Q2 FY2026 Results Briefing Transcript
M impact | EQUITY | Nov 03, 2026, 11:53 PM UTC
Triple Flag Precious Metals Reports Quarterly Results
Triple Flag Precious Metals reported results for the quarter ended September 30.
M impact | EQUITY | Nov 03, 2026, 11:53 PM UTC
PACS Group Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 03, 2026, 11:49 PM UTC